These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prevalence and antimicrobial resistance among Campylobacter spp. in Louisiana retail chickens after the enrofloxacin ban.
    Author: Han F, Lestari SI, Pu S, Ge B.
    Journal: Foodborne Pathog Dis; 2009 Mar; 6(2):163-71. PubMed ID: 19099357.
    Abstract:
    Effective in September 2005, enrofloxacin, a fluoroquinolone group antimicrobial, was withdrawn from use in the U.S. poultry farms. In this 1-year study initiated in October 2006, we isolated and characterized Campylobacter spp. from Louisiana retail conventionally raised (n = 141) and organic (n = 53) chickens as a comparison to evaluate the postban bacterial resistance to antimicrobials. Campylobacter was present in 43.3% of the chickens; similar rates were observed among conventional and organic chickens. A total of 165 Campylobacter isolates were recovered, with Campylobacter jejuni being the predominant species (66.7%). No apparent seasonal trend was deduced from the prevalence data. Further, the two main conventional and one organic chicken brands did not carry significantly different rates of Campylobacter (p > 0.05). The most common resistance observed was to tetracycline (31.5%), followed by erythromycin (20%) and ciprofloxacin (6.1%). No resistance to gentamicin was identified. All Campylobacter isolates recovered from organic chickens (n = 48) were susceptible to ciprofloxacin, compared to 8.5% resistance rate for those from conventional chickens (n = 117). Additionally, the resistance rate to erythromycin was significantly higher in Campylobacter isolates from conventional chickens (23.9%) than those from organic chickens (10.4%; p < 0.05). Our results demonstrated a low prevalence and low ciprofloxacin resistance rate of Campylobacter in Louisiana retail chickens after the enrofloxacin ban. Further studies involving a larger sample size over time are warranted to better assess the effects of banning enrofloxacin use in poultry and the levels of fluoroquinolone-resistant Campylobacter.
    [Abstract] [Full Text] [Related] [New Search]